Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Pericapsular Nerve Group (PENG) block is an effective method for postoperative pain management in patients undergoing primary total hip arthroplasty (THA) via a posterolateral approach. The application of this technique reduces postoperative opioid requirements, thereby limiting the risk of adverse effects associated with systemic opioid administration. Effective pain control and a reduced incidence of side effects may translate into higher patient satisfaction and a decreased length of hospital stay (LOS). The PENG block serves as an effective component of multimodal analgesia and may provide an alternative to intrathecal morphine in patients undergoing primary total hip arthroplasty via a posterolateral approach, where the primary anesthetic technique is spinal anesthesia with hyperbaric bupivacaine.
Objectives
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PENG Group | Experimental | Spinal anesthesia without opioid + PENG block |
|
| MF Group | Active Comparator | Spinal anesthesia with opioid and sham PENG Block |
|
| Control | Sham Comparator | Spinal anesthesia without opioid and sham PENG Block |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PNEG block | Procedure | Pericapsular Nerve Group (PENG) block will be performed using 20 mL of 0.5% ropivacaine (Ropimol, Molteni, Italy), supplemented with 4 mg of dexamethasone (Dexaven, Bausch Health, Ireland). |
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative oxycodone consumption delivered via patient-controlled analgesia (PCA) | Total amount of oxycodone delivered by the intravenous PCA pump, calculated as the sum of all delivered PCA boluses and reported in milligrams. Lower values indicate lower postoperative opioid requirement. | From end of surgery to 24 hours postoperatively. |
| Number of patient-initiated PCA demand attempts recorded by the PCA pump | Total number of patient-initiated analgesia requests (button presses) recorded by the intravenous patient-controlled analgesia (PCA) pump. This measure includes all demand attempts, regardless of whether a bolus was delivered. Reported as count. | From end of surgery to 24 hours postoperatively. |
| Pain intensity at rest measured by the 11-point Numerical Rating Scale (NRS, 0-10) | Patient-reported pain intensity at rest assessed using the 11-point Numerical Rating Scale (NRS), where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate worse pain. Pain score is recorded at each scheduled assessment time point. | Baseline (day before surgery), and at 0, 4, 8, 12, and 24 hours after surgery. |
| Dynamic pain assesmnetDynamic pain intensity during passive straight leg raise measured by the 11-point Numerical Rating Scale (NRS, 0-10) | Patient-reported dynamic pain intensity during passive straight leg raise of the operated limb (knee extended and hip flexed to 45°), assessed using the 11-point Numerical Rating Scale (NRS), where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate worse pain. Pain score is recorded at each scheduled assessment time point. | Baseline (day before surgery), and at 0, 4, 8, 12, and 24 hours after surgery. |
| Patient satisfaction with postoperative analgesia measured by a 5-point Likert satisfaction scale (1-5) |
| Measure | Description | Time Frame |
|---|---|---|
| Nausea severity | Assessment via a Visual Analogue Scale (VAS), where "0" indicates no nausea and "10" indicates the most severe nausea | Assessed on the day before surgery and at 0, 4, 8, 12, and 24 hours postoperatively |
| Pruritus Severity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mykhailo Kazantsev, MD | Contact | 00 48 56 641 4039 | mykhailo.kazantsev@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Radosław Owczuk, MD, PhD, Prof. | Medical Unitersity of Gdansk | Study Chair |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Spinal anesthesia with opioid | Procedure | Spinal anesthesia will be administered using 0.5% hyperbaric bupivacaine, supplemented with 100 mcg of morphine (Morphini Sulfas WZF 0.1% Spinal, Polpharma, Poland). |
|
| Spinal anesthesia without opioid | Procedure | Spinal anesthesia will be administered using 0.5% hyperbaric bupivacaine (Marcaine Spinal 0.5% Heavy, Aspen Pharma, Ireland). |
|
| Sham PENG block | Procedure | A sham PENG block will be performed using 20 mL of 0.9% sodium chloride solution (Natrium chloratum 0,9% Fresenius, Fresenius Kabi, Poland). |
|
Patient-reported satisfaction with postoperative analgesia assessed using a 5-point Likert satisfaction scale:
| At 0, 4, 8, 12, and 24 hours after surgery. |
Assessment via a Visual Analogue Scale (VAS), where "0" indicates no pruritus and "10" indicates the worst possible itching
| Assessed on the day before surgery and at 0, 4, 8, 12, and 24 hours postoperatively |
| Postoperative length of hospital stay (days) | Duration from hospital admission to hospital discharge, reported in days. | From hospital admission to hospital discharge (assessed at hospital discharge). |
| Sedation and agitation level measured by the Richmond Agitation-Sedation Scale (RASS, -5 to +4) | Sedation/agitation is assessed using the Richmond Agitation-Sedation Scale (RASS), ranging from -5 to +4, where:
| At 0, 4, 8, 12, and 24 hours after surgery. |
| Motor blockade measured by the Bromage motor blockade scale (Grade 0-3) | Motor blockade is assessed using the Bromage motor blockade scale from Grade 0 to Grade 3, where: Grade 0 = no motor blockade (full movement at knee and ankle joints), Grade 1 = partial block (limited/simple knee movement, full foot movement), Grade 2 = almost complete block (no knee movement, preserved foot movement), Grade 3 = complete block (no movement of lower limbs, including knees and feet). Higher grades indicate greater motor blockade (worse motor function). Lower grades indicate less motor blockade (better motor function recovery). | At 0, 4, 8, 12, and 24 hours after surgery. |
| Sensory blockade | Evaluation of the spinal anesthesia level based on thermal sensation (using an antiseptic spray) | At 0, 4, 8, 12, and 24 hours postoperatively. |
| Antiemetic Consumption | Total dose of ondansetron and/or other antiemetics administered. | Within the first 24 hours following the completion of surgery |
| Intraoperative blood loss (mL) | Estimated blood loss during surgery, reported in milliliters (mL). | Intraoperatively (from skin incision to skin closure). |
| Duration of surgery (minutes) | Time from skin incision to skin closure, reported in minutes. | Intraoperatively (from skin incision to skin closure). |
| Participants requiring intraoperative vasopressors | Number of participants who required at least one vasopressor dose during surgery, reported as count. | Intraoperatively (from skin incision to skin closure). |
| Heart rate (beats per minute) | Heart rate measured by bedside monitoring and reported in beats per minute (bpm). | Baseline (day before surgery), and at 0, 4, 8, 12, and 24 hours after surgery. |
| Peripheral oxygen saturation (SpO2, %) | Peripheral oxygen saturation measured by pulse oximetry and reported as percent (%). | Baseline (day before surgery), and at 0, 4, 8, 12, and 24 hours after surgery. |
| Diastolic blood pressure (DBP, mmHg) | Non-invasive diastolic blood pressure measured with an automated cuff and reported in mmHg. | Baseline (day before surgery), and at 0, 4, 8, 12, and 24 hours after surgery. |
| Mean arterial pressure (MAP, mmHg) | Mean arterial pressure reported in mmHg at each assessment time point (device-reported value or calculated from SBP and DBP, per site standard). | Baseline (day before surgery), and at 0, 4, 8, 12, and 24 hours after surgery. |
| Time to first mobilization (hours) | Time interval from administration of spinal anesthesia to first mobilization, defined as first upright positioning and/or ambulation, reported in hours. | From administration of spinal anesthesia until hospital discharge (time to first mobilization assessed at first mobilization, through study completion an average of 24 hours postoperatively). |
| Number of participants with predefined anesthesia-related complications | Number of participants with at least one predefined anesthesia-related complication, including accidental vascular puncture, local anesthetic systemic toxicity (LAST), and respiratory failure. Reported as count. | From hospital admission to hospital discharge (assessed daily during hospitalization and at discharge, through study completion an average 5 days postoperatively). |
| Number of participants with predefined hospitalization-related complications | Number of participants with at least one predefined hospitalization-related complication, including requirement for blood product transfusion, pneumonia, cardiovascular events, and surgical site infection (SSI). Reported as count. | From hospital admission to hospital discharge (assessed daily during hospitalization and at discharge, through study completion an average 5 days postoperatively). |
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000775 | Anesthesia, Spinal |
| D000701 | Analgesics, Opioid |
| ID | Term |
|---|---|
| D000765 | Anesthesia, Conduction |
| D000758 | Anesthesia |
| D000760 | Anesthesia and Analgesia |
| D009294 | Narcotics |
| D002492 | Central Nervous System Depressants |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D000700 | Analgesics |
| D018689 | Sensory System Agents |
| D018373 | Peripheral Nervous System Agents |
| D002491 | Central Nervous System Agents |
| D045506 | Therapeutic Uses |
Not provided
Not provided